[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"short-bowel-syndrome-sbs\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:short-bowel-syndrome-sbs":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,47,74,101,124],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100615794","effect-of-glp-1-on-intestinal-barrier-function-in-sbs-if-patients-a-preliminary-exploration-100615794",false,"NCT07297238","Effect of GLP-1 on Intestinal Barrier Function in SBS-IF Patients: A Preliminary Exploration.","Therapeutic Efficacy of GLP-1 on Intestinal Barrier Function in Patients With Short Bowel Syndrome and Intestinal Failure: A Preliminary Randomized Controlled Trial","Inclusion Criteria:\n\n* Participants voluntarily provided written informed consent for this trial;\n* Aged 18 to 80 years, inclusive, regardless of gender;\n* With stable vital signs;\n* Diagnosis of SBS-IF, confirmed by existing medical\u002Fsurgical records, receiving parenteral nutrition (PN) due to surgical resection of the small intestine (\\\u003C200 cm from the duodenojejunal flexure), and meeting one of the following criteria:\n\n  * Colon continuity maintained without jejunal\u002Fileal stoma (Type II or III);\n\n    * Presence of a jejunostomy or ileostomy (Type I);\n* Expected requirement of PN for more than 4 weeks, with an average PN caloric intake ≥80%;\n* Ability to comply with the medication dosing and visit schedule;\n* Capacity to accurately describe symptoms, absence of severe infections or respiratory insufficiency, and willingness to cooperate proactively;\n* No history of allergic diseases, non-allergic constitution, and no hypersensitivity to any component of semaglutide injection;\n* No history of drug abuse;\n* Not pregnant or lactating; no pregnancy plans within one month after the trial (applies to both female and male participants);\n* No participation in any other drug trials (including the investigational product in this study) within three months prior to enrollment.\n\nExclusion Criteria:\n\n* Individuals who do not meet the inclusion criteria or are deemed ineligible by the investigator;\n* Poor general condition, inability to accurately describe symptoms, presence of severe infection, respiratory insufficiency, or other conditions that may hinder active cooperation;\n* History of allergic diseases, allergic constitution, or hypersensitivity to drugs structurally related to the investigational product;\n* Patients with malignancy at any site;\n* Those with psychiatric disorders, inability to cooperate, or impaired consciousness;\n* Patients with contraindications to the investigational drug (including personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2);\n* Immunodeficiency, or current use of immunosuppressants or corticosteroids;\n* Immediate family members of the sponsor, investigator, or study staff directly involved in the trial;\n* Any other condition considered by the investigator as grounds for exclusion.","ALL","18 Years","80 Years",{"count":20,"type":21},20,"ESTIMATED","INTERVENTIONAL",[24],"NA","Eligible patients were randomized into two groups: the GLP-1 group and the control group. The control group received a placebo along with standard care, without any additional GLP-1-based intervention. The GLP-1 group, in addition to standard care, received a subcutaneous injection of a GLP-1 analog (semaglutide injection) strictly according to the drug manufacturer's instructions. The initial dose of semaglutide was 0.25 mg once weekly. Treatment was continued over a 28-days period. Primary and secondary outcomes will be collected.",[27,28],"Short Bowel Syndrome (SBS)","Intestinal Failure",[30,31,32,33],"GLP-1","short bowel syndrome","intestinal failure","Intestinal Barrier Function","RECRUITING","2026-05-27",{"date":37,"type":38},"2026-05-28","ACTUAL",{"date":40,"type":38},"2026-01-24",{"date":42,"type":21},"2026-06-30",{"name":44,"class":45},"Jinling Hospital, China","OTHER",2,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":22,"phases":57,"briefSummary":58,"conditions":59,"keywords":60,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":4},"100633697","role-of-the-microbiota-in-intestinal-adaptation-during-short-bowel-syndrome-100633697","NCT07530055","Role of the Microbiota in Intestinal Adaptation During Short Bowel Syndrome","Role of the Microbiota in Intestinal Adaptation During Short Bowel Syndrome: a Longitudinal Follow-up","AdMIR","Inclusion Criteria:\n\n* Age ≥18 years\n* Diagnosis of short bowel syndrome with a jejunostomy and a plan to restore jejuno-colic continuity within 3 months\n* Remaining post-duodenal small intestine (after the ligament of Treitz) \\\u003C 200 cm\n* Remaining colon \\> 14%\n* Remaining small intestine and colon are healthy (no residual inflammatory, post-radiation, or ischemic disease)\n* Patient enrolled in a social security system or entitled to coverage\n\nExclusion Criteria:\n\n* Pregnancy\n* Patient unable to provide consent:\n* Due to a disability preventing consent\n* Does not understand French\n* Patient deprived of liberty, or under legal protection (guardianship or curatorship)\n* Participation in another interventional study",{"count":56,"type":21},15,[24],"During the first years following intestinal resection, spontaneous physiological adaptations occur in patients with short bowel syndrome (SBS), allowing improvement of the absorptive capacity of the remaining intestine. This adaptation is particularly effective in SBS patients with the colon in continuity. The specific relationship between this intestinal adaptation and changes in the gut microbiota has not been studied in these patients. We hypothesize that there is a specific relationship between the microbiota and its metabolites and intestinal adaptive capacity, and that certain gut bacteria may promote this spontaneous adaptation.",[27],[61,62,63],"Short Bowel Syndrome","Intestinal Adaptation","Gastrointestinal Microbiome","NOT_YET_RECRUITING","2026-04-08",{"date":67,"type":38},"2026-04-15",{"date":69,"type":21},"2026-04",{"date":71,"type":21},"2029-02",{"name":73,"class":45},"Assistance Publique - Hôpitaux de Paris",{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":4,"eligibilityCriteria":80,"healthyVolunteers":11,"sex":16,"minAge":81,"maxAge":82,"enrollmentInfo":83,"targetDuration":4,"studyType":85,"phases":4,"briefSummary":86,"conditions":87,"keywords":88,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":100},"100617531","a-study-of-teduglutide-in-chinese-children-and-teenagers-with-short-bowel-syndrome-100617531","NCT07319832","A Study of Teduglutide in Chinese Children and Teenagers With Short Bowel Syndrome","A Multicenter, Retrospective and Prospective, Observational Study to Evaluate the Efficacy and Safety of Subcutaneous Teduglutide in the Treatment of Short Bowel Syndrome (SBS) in Parenteral Nutrition (PN) Dependent Chinese Pediatric Subjects (≥1 Through 17 Years Old)","Inclusion criteria\n\n* Children and adolescents greater than or equal to (\\>=)1 through 17 years of age at Day 1 (D1).\n* Documented diagnosis of SBS.\n* Received or plan to receive Teduglutide treatment for a minimum of 24 weeks.\n* Stable PN\u002FIV support, defined as inability to significantly reduce PN\u002FIV support, usually associated with minimal or no advance in enteral feeds (i.e., 10% or less change in PN or advance in feeds) for at least 3 months prior to D1, as assessed by the investigator. Transient instability for events such as interruption of central access or treatment for sepsis is allowed if the PN\u002FIV support returns to within 10% of baseline prior to the event.\n* Informed consent obtained from the patient aged 8 to 17 years and their guardians, while informed consent from the guardians for participants under 8 years old, unless waived by the Institution's Ethics Committee.\n\nExclusion criteria\n\n* Participants who are not expected to be able to advance oral or tube feeding regimens.\n* Serial Transverse Enteroplasty (STEP) or any other bowel lengthening procedure performed within 3 months prior to baseline.\n* Known clinically significant untreated intestinal obstruction contributing to feeding intolerance and inability to reduce PS.\n* Evidence of clinically significant obstruction on upper GI series done within 6 months prior to baseline.\n* Previous use of octreotide or Dipeptidyl peptidase-4 (DPP-4) inhibitors within 3 months prior to baseline.\n* Signs of active, severe, or unstable clinically significant hepatic impairment during the screening or baseline period, indicative by any of the following laboratory test results:\n\n  1. Total Bilirubin Level (TBL) \\>= 2 × upper limit of normal (ULN)\n  2. Aspartate Aminotransferase (AST) \\>=7 × ULN\n  3. Alanine Aminotransferase (ALT) \\>=7 × ULN\n\n     For Participants with Gilbert's disease:\n  4. Indirect (unconjugated) bilirubin \\>=2 × ULN\n* Signs of known continuous active or unstable, clinically significant renal dysfunction shown by results of an estimated glomerular filtration rate (eGFR) below 50 millilitres per minutes per 1.73 meter square (mL\u002Fmin\u002F1.73 m\\^2).\n* Known hypersensitivity of the active substance or excipient of teduglutide.\n* Body weight less than (\\\u003C) 10 kg at baseline.\n* Previous use of teduglutide or native\u002Fsynthetic Glucagon-like Peptide-2 (GLP-2).\n* Previous use of GLP-1 analog or human growth hormone within 3 months prior to baseline.\n* Any condition, disease, illness, or circumstance that in the investigator's opinion puts the patient at any undue risk, prevents completion of the study, or interferes with analysis of the study results.","1 Year","17 Years",{"count":84,"type":21},12,"OBSERVATIONAL","Short Bowel Syndrome (SBS) is a rare condition that happens when a large part of the bowel (also called intestine) is missing or has been removed because of illness or surgery. In children, SBS means that the intestine cannot absorb enough food, water and important part of food the body needs (called nutrients) because a big part of it has been removed, bypassed or did not develop normally at birth and the children need support through a vein (parenteral support or PS) for more than 42 days to stay healthy and keep their energy. SBS in children is defined mainly by how well the intestine works and how long the children need this support, not just by how long the intestine is.\n\nThe main aim of the study is to learn how well the teduglutide works in children and teenagers with SBS and who need PS. Another aim is to find out how well teduglutide works for participants to lower the amount of PS needed. Also, the study wants to learn more about how safe teduglutide is in children and teenagers with SBS who need PS.\n\nThe study will review data already existing in the medical records of participants as well as collect new data during the study.",[27],[89],"Drug Therapy","2026-03-11",{"date":92,"type":38},"2026-03-13",{"date":94,"type":38},"2026-03-05",{"date":96,"type":21},"2027-09-30",{"name":98,"class":99},"Takeda","INDUSTRY",4,{"id":102,"slug":103,"hasResults":11,"nctId":104,"briefTitle":105,"officialTitle":106,"acronym":4,"eligibilityCriteria":107,"healthyVolunteers":11,"sex":16,"minAge":108,"maxAge":82,"enrollmentInfo":109,"targetDuration":4,"studyType":22,"phases":111,"briefSummary":112,"conditions":113,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":114,"lastUpdatePostDateStruct":115,"startDateStruct":117,"completionDateStruct":119,"leadSponsor":121,"locationsCount":123},"100623757","tedorg-study-on-short-bowel-syndrome-100623757","NCT07400783","TED_ORG: Study on Short Bowel Syndrome","Short Bowel Syndrome: Human Intestinal Organoids to Investigate the Different Efficacy of the GLP-2 Analogue Teduglutide in Pediatric Patients With Short Bowel Syndrome","Inclusion Criteria:\n\n* Patients or His\u002Fher Parents\u002F legal guardian must provide informed consent before they can participate in the study.\n* Paediatric patients: Male and female patients aged ≥ 4 months old and ≤ 18 years;\n* SBS patient or patient undergoing intestinal resective surgery\n\nExclusion Criteria:\n\n* Adult patients (≥ 18 years old);\n* Patients who have never undergone intestinal resective surgery\n* Current or past use of teduglutide","4 Months",{"count":110,"type":21},50,[24],"The goal of this clinical trial is to understand why pediatric patients with short bowel syndrome respond differently to treatment with the glucagon-like peptide-2 (GLP-2) analogue teduglutide. Short bowel syndrome is a rare and severe condition in children that results from extensive intestinal resection and leads to impaired nutrient absorption, chronic diarrhea, and dependence on parenteral nutrition. Although teduglutide is known to promote intestinal adaptation and improve absorption, the clinical response varies widely among patients, and the biological mechanisms underlying this variability are not fully understood.\n\nThis study aims to investigate the effects of teduglutide using human intestinal organoids derived from intestinal tissue samples of pediatric patients with short bowel syndrome. Intestinal organoids are three-dimensional structures grown from patient-derived stem cells that reproduce key structural and functional characteristics of the human intestine. These organoids provide a human-based experimental model that allows the study of intestinal morphology, cellular behavior, and nutrient absorption in a controlled in vitro environment.\n\nThe main questions this study aims to answer are:\n\nDoes treatment with teduglutide improve the absorptive capacity of human intestinal organoids derived from pediatric patients with short bowel syndrome?\n\nAre there differences in intestinal structure, cellular proliferation, and gene expression between teduglutide-treated organoids and untreated organoids?\n\nAre specific molecular or cellular features associated with different responses to teduglutide?\n\nResearchers will compare intestinal organoids treated with teduglutide to untreated organoids obtained from the same patients. This comparison will be used to evaluate changes in organoid morphology, expression of receptors involved in intestinal growth and absorption, activity of nutrient transporters, and overall absorptive function. The study will also explore differences between organoids derived from patients who show different clinical responses to teduglutide.\n\nParticipants in this study are pediatric patients with short bowel syndrome or patients undergoing intestinal resection surgery as part of their standard clinical care. No experimental treatment is administered directly to participants as part of this study. Intestinal tissue samples are collected only during clinically indicated surgical procedures and are not obtained specifically for research purposes.\n\nParticipants will:\n\nProvide intestinal tissue samples collected during routine or clinically indicated intestinal surgery\n\nHave intestinal organoids generated from their tissue samples using established laboratory techniques\n\nHave their organoids studied in vitro with and without exposure to teduglutide to evaluate intestinal structure, gene and protein expression, and nutrient absorption mechanisms\n\nThe results of this study are expected to improve understanding of the biological mechanisms underlying variable responses to teduglutide and may contribute to the development of more personalized treatment strategies for pediatric patients with short bowel syndrome in the future.",[27],"2026-02-06",{"date":116,"type":38},"2026-02-10",{"date":118,"type":38},"2024-10-30",{"date":120,"type":21},"2026-10",{"name":122,"class":45},"Meyer Children's Hospital IRCCS",1,{"id":125,"slug":126,"hasResults":11,"nctId":127,"briefTitle":128,"officialTitle":129,"acronym":4,"eligibilityCriteria":130,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":131,"targetDuration":4,"studyType":85,"phases":4,"briefSummary":133,"conditions":134,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":135,"lastUpdatePostDateStruct":136,"startDateStruct":138,"completionDateStruct":140,"leadSponsor":142,"locationsCount":123},"100482408","a-survey-to-assess-participants-and-physicians-knowledge-when-using-gattex-knowledge-assessment-survey-100482408","NCT05561647","A Survey to Assess Participants' and Physicians' Knowledge When Using GATTEX (Knowledge Assessment Survey)","Quantitative Testing of Patient and Prescriber Knowledge About GATTEX (Teduglutide) for Injection Safety and Use Information","Participant inclusion criteria:\n\nParticipants who are 18 years of age and who have taken GATTEX in the 60 days prior to survey implementation are eligible to participate in the survey. A caregiver may participate in this survey on behalf of a participant who is eligible but unable to complete the survey. Note: Participants who have previously participated in a GATTEX Patient Knowledge Assessment Survey, are eligible.\n\nPrescriber inclusion criteria:\n\nHCPs (adult and pediatric) in the United States who can provide a 10-digit National Provider Identifier (NPI) number and who have prescribed GATTEX at least once regardless of their completion of the voluntary GATTEX REMS training (Prescriber Education Slide Deck) are eligible for participation in the survey. Note: HCPs who have previously participated in a GATTEX Prescriber Knowledge Assessment Survey, are eligible\n\nParticipant and Prescriber exclusion criteria:\n\n* Respondents who do not agree to participate in the survey.\n* Respondents who are currently working for and\u002For whose immediate family members who are currently working for Takeda Pharmaceuticals U.S.A., Inc., NPS Pharmaceuticals, Inc., Shire, UBC, or the Food and Drug Administration (FDA) are not eligible to participate in the survey.\n* Respondents who reported having a conflict of interest.\n* HCPs who have opted out of receiving communications about the GATTEX Prescriber Knowledge Assessment Survey for the current wave\n\nFurther details associated with respondents who do not meet the exclusion criteria established above, will be provided in the assessment report.",{"count":132,"type":21},600,"The study is about learning and documenting how well participants and physicians understand how to use GATTEX and about potential risks by using a survey (called Knowledge Assessment Survey). This survey, which is conducted every two years, is part of the Gattex Risk Evaluation and Mitigation Strategy (REMS). REMS is a safety program required by the US health authority (FDA) for certain medicines that have serious risks. REMS intends to help reduce these risks while still allowing treatment. The goal is to make sure these medicines are used in the safest way possible. The main aim of this survey is to find out how well participants and physicians understand the checkups and tests (so called monitoring) participants should have while taking GATTEX, and the possible risks or of using GATTEX to treat Short Bowel Syndrome.\n\nThe knowledge assessment survey will be done via internet, telephone, or paper and both physicians and participants will be able to choose the method that is preferred.\n\nNo study medicines will be provided to participants in this study.",[27],"2026-01-23",{"date":137,"type":38},"2026-01-26",{"date":139,"type":38},"2013-08-01",{"date":141,"type":21},"2031-12-31",{"name":98,"class":99}]